Shuguang Yuan
Cofounder Alphamol
Dr Shuguang Yuan finished his doctoral dissertation with the supports of Maria Curia Fellowship. It was conducted in three different institutes in Europe, including Swiss Federal Institute of Technology Lausanne (EPFL, Switzerland), Polish Academy of Science (Poland) and KULeuven University (Belgium). He has been in the list of “Global Top 2% Scientists” since 2022.
His research is mainly focusing on G protein-coupled receptors (GPCRs) molecular mechanism as well as drug discovery via computational biology and artificial intelligence.
In June 2013, he was awarded with a PhD title with the honor of distinguished thesis. Following that, he was offered the Marie Curie ETH Postdoc Fellowship. In 2014, Dr. Yuan proposed a theory about the activation mechanism and the continuous water channel of GPCRs, which could be used to guide the design of agonist/antagonist molecules.
Furthermore, Dr. Yuan worked in big pharma in Basel in Switzerland for several years. He has advanced several of his designed molecules into clinical trials successfully.
Seminars
- How can dynamic modeling, data integration, and cross-disciplinary collaboration be connected to create a truly cohesive GPCR discovery ecosystem?
- What operational barriers must be overcome to achieve genuine AI-enabled translational science across academia and industry?
- What does the roadmap look like for structure-guided and AI-assisted GPCR discovery to reshape drug development over the next decade?
- Leveraging advanced computational methods to discover and verify a high-potential orphan GPCR linked to our disease of interest
- Pursuing the project against investor and industry skepticism, supported by strong clinical evidence and a differentiated indication strategy
- Presenting early clinical results from Phase 1 trial
